Drug General Information (ID: DDIML6T0WY)
  Drug Name Aliskiren Drug Info Potassium acetate Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Minerals And Electrolytes
  Structure

 Mechanism of Aliskiren-Potassium acetate Interaction (Severity Level: Moderate)
     Increased risk of hyperkalemia Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Aliskiren Potassium acetate
      Mechanism Hyperkalemia Hyperkalemia
      Key Mechanism Factor 1
Factor Name Hyperkalemia
Factor Description Hyperkalemia is a condition in which the level of potassium in the blood is higher than normal. While mild cases may not produce symptoms, severe hyperkalemia can lead to fatal arrhythmias if left untreated.
      Mechanism Description
  • Increased risk of hyperkalemia by the combination of Aliskiren and Potassium acetate 

Recommended Action
      Management Caution is advised if aliskiren is used in combination with potassium-sparing diuretics or potassium salts. Routine monitoring of electrolytes and renal function may be indicated, particularly in patients with renal impairment, diabetes, old age, worsening heart failure, or a risk for dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as weakness, listlessness, confusion, tingling of the extremities, and irregular heartbeat.

References
1 Product Information. Tekturna (aliskiren). Novartis Pharmaceuticals, East Hanover, NJ.